Gregory Stafford

My hon. Friend is a great champion for his constituents, especially on this issue but on others as well. He is absolutely right that while the committee is making its evidential findings, there is nothing to stop the Government promoting a number of these ways to make sure that those at highest risk are getting treatment as soon as possible. Cancer Research UK has highlighted the risks too. As my hon. Friend said, screening must be evidence-led, but Transform exists to address the limits of existing evidence, and improvements in testing and MRI-led pathways offer ways to improve how men are assessed, as many Members have mentioned. Uncertainty must not be the end; it must lead to research and progress, not delay. The former shadow Health Secretary, my right hon. Friend the Member for Daventry (Stuart Andrew), set out the position of His Majesty’s Opposition last August. He said we would “back the latest evidence and research to ensure patient care remains at the heart of testing guidance.” That is clearly the right approach: act where the evidence supports it, accelerate research where questions remain, and be clear about when decisions will be made. Men must not be disadvantaged by circumstances beyond their control. One may have no family records because his father died young, for example; another may simply want to discuss his risk with his GP. As my right hon. Friend said, no man with potential prostate cancer symptoms should be denied a test because of poor family records. To conclude, His Majesty’s loyal Opposition support targeted screening for men at highest risk, Transform and the committee’s evidence-led approach. But we need clear guidance from the Government on PSA testing, practical support for men at the highest risk, a credible plan to identify BRCA2 carriers and a dated timetable for the model, with independent scrutiny of it and transparency about how Transform will shape policy. I hope the Minister will address those questions directly now; if not, will she write to me and set out clearly what patients can expect next?